S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

$53.80
-0.40 (-0.74 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$53.39
Now: $53.80
$54.63
50-Day Range
$39.02
MA: $45.23
$54.20
52-Week Range
$30.38
Now: $53.80
$63.21
Volume261,792 shs
Average Volume389,747 shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.83
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$218.51 million
Cash Flow$2.57 per share
Book Value$14.20 per share

Profitability

Net Income$99.94 million

Miscellaneous

Employees192
Market Cap$1.98 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.


Regenxbio (NASDAQ:RGNX) Frequently Asked Questions

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) released its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.91) by $0.03. The biotechnology company had revenue of $14.70 million for the quarter, compared to analysts' expectations of $7.46 million. Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. The business's quarterly revenue was up 177.0% on a year-over-year basis. During the same period last year, the firm earned ($0.56) EPS. View Regenxbio's Earnings History.

When is Regenxbio's next earnings date?

Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Regenxbio.

What price target have analysts set for RGNX?

6 brokers have issued 1-year target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's stock price to reach $77.50 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for Regenxbio.

What is the consensus analysts' recommendation for Regenxbio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

Has Regenxbio been receiving favorable news coverage?

News stories about RGNX stock have trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regenxbio earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Regenxbio.

Who are some of Regenxbio's key competitors?

What other stocks do shareholders of Regenxbio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Visa (V), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), Square (SQ), Alibaba Group (BABA), Immunomedics (IMMU) and Micron Technology (MU).

Who are Regenxbio's key executives?

Regenxbio's management team includes the folowing people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
  • Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
  • Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
  • Dr. Olivier Danos, Chief Scientific Officer (Age 61)
  • Dr. Stephen Yoo, Consultant (Age 41)

Who are Regenxbio's major shareholders?

Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.10%), UBS Group AG (1.78%), Credit Suisse AG (1.38%), Kam Lawrence (1.27%), Korea Investment CORP (1.24%) and Goldman Sachs Group Inc. (1.19%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

Which institutional investors are selling Regenxbio stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rafferty Asset Management LLC, Bank of New York Mellon Corp, Citigroup Inc., SG Americas Securities LLC, P.A.W. Capital Corp, AQR Capital Management LLC and Franklin Resources Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

Which institutional investors are buying Regenxbio stock?

RGNX stock was purchased by a variety of institutional investors in the last quarter, including Kam Lawrence, UBS Group AG, Goldman Sachs Group Inc., Barclays PLC, Parkman Healthcare Partners LLC, Panagora Asset Management Inc., Rhenman & Partners Asset Management AB and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Regenxbio.

How do I buy shares of Regenxbio?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Regenxbio's stock price today?

One share of RGNX stock can currently be purchased for approximately $53.80.

How big of a company is Regenxbio?

Regenxbio has a market capitalization of $1.98 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

What is Regenxbio's official website?

The official website for Regenxbio is http://www.regenxbio.com/.

How can I contact Regenxbio?

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]


MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: VIX - Volatility Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel